Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665117 · ClinicalTrials.gov registry record · NA
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT02665117 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 61 participants.
The verdict
NCT02665117, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia, activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia, Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may interact with each other to contribute to the development of insulin resistances and metabolic syndrome. Smaller studies have suggested that Potassium magnesium Citrate (KMgCit) can ameliorate CTD- induced metabolic side effects independent of correction of hypokalemia. This study will tests if KMgCit ameliorates CTD induced metabolic effects independent of correction of hypokalemia.
Interventions
- DRUG Chlorthalidone
- DRUG Potassium Magnesium Citrate (KMgCit)
- DRUG Potassium Chloride (KCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-01 |
| Est. Completion | 2022-11-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665117
The ClinicalTrials.gov registry entry for NCT02665117 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Chlorthalidone is the first listed.
NCT02665117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02665117 about?
NCT02665117 is a clinical study titled "Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate". Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia, activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia, Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may interact with each other to con...
What is the current status of trial NCT02665117?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2015-01. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT02665117?
The interventions under investigation include: Chlorthalidone (DRUG), Potassium Magnesium Citrate (KMgCit) (DRUG), Potassium Chloride (KCl) (DRUG).
Who is sponsoring clinical trial NCT02665117?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.